Mixed Dyslipidemia clinical trials

Explore recruiting mixed dyslipidemia clinical trials.

Recruiting mixed dyslipidemia studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Mixed Dyslipidemia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Trial Evaluating the Efficacy and Safety of RBD5044 in Patients with Mixed Dyslipidemia

Sweden, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of ARO-APOC3 in Adults with Dyslipidemia

Poland, Hungary, Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

Mixed Dyslipidemia trials by city

Mixed Dyslipidemia in Toronto Mixed Dyslipidemia in Vancouver Mixed Dyslipidemia in Montreal Mixed Dyslipidemia in Calgary Mixed Dyslipidemia in Edmonton Mixed Dyslipidemia in Ottawa Mixed Dyslipidemia in Winnipeg Mixed Dyslipidemia in Quebec City Mixed Dyslipidemia in Hamilton Mixed Dyslipidemia in Kitchener Mixed Dyslipidemia in London Mixed Dyslipidemia in Halifax Mixed Dyslipidemia in New York Mixed Dyslipidemia in Los Angeles Mixed Dyslipidemia in Chicago Mixed Dyslipidemia in Houston

Mixed Dyslipidemia clinical trials

Recruiting mixed dyslipidemia studies right now

Study of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia

A Study to Compare to PK Characteristics and Safety Profiles Between PA-111 and PA-111A

Efficacy and Safety of JS002 as Monotherapy in Patients With Primary Hypercholesterolaemia and Mixed Dyslipidemia

Phase 2 Trial Evaluating the Efficacy and Safety of RBD5044 in Patients With Mixed Dyslipidemia

Phase 3 Clinical Study Evaluating Efficacy, Safety, and Tolerability of Obicetrapib Vs Bempedoic Acid to Treat Dyslipidemia in Adults With Primary Non-familial Hypercholesterolemia or Mixed Dyslipidemia at High to Very High Cardiovascular Risk, During a Treatment Period of Approximately 84 Days

WeArable teChnology daTa driVen digitAl healTh cOachINg (ACTIVATION)- A Mixed-methods Study

A Study to Evaluate the Safety, Efficacy of SYH2053 as Monotherapy in Chinese Participants With Non-familial Hypercholesterolemia or Mixed Hyperlipidemia

A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias

A Study to Evaluate the Efficacy and Safety of AD-218

A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia

Targeting Metabolic Syndrome From the Emergency Department Through Mixed-Methods: Pilot Trial

IBI306 Monotherapy in Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia

Also recruiting in Europe

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Trial Evaluating the Efficacy and Safety of RBD5044 in Patients with Mixed Dyslipidemia

A Phase 2 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of ARO-APOC3 in Adults with Dyslipidemia

Mixed Dyslipidemia trials by city

Other conditions